A Multi-center, Open-label Study to Investigate the Safety/Tolerability and Efficacy of Ligelizumab (QGE031) in the Treatment of Adult Japanese Patients With Chronic Spontaneous Urticaria (CSU) Inadequately Controlled With H1 Antihistamines
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Safety and Tolerability of Ligelizumab 120 mg q4w Treatment for 12 Months
研究概览
简要总结
The purpose of this study was to evaluate the safety and efficacy of ligelizumab in adult Japanese subjects with CSU, who remain symptomatic despite treatment with H1-antihistamines (AHs) at locally approved doses.
The study population consisted of 66 male and female subjects aged ≥ 18 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-AH.
This was a Phase III multi-center, open-label, single arm study. There was a screening period of up to 28 days, a 52 week treatment period, and a 12 week post-treatment follow-up period.
详细描述
This was a Phase III multi-center, open-label, single arm study. The study consisted of 3 distinct periods:
Screening period (Day -28 to Day -14): Subjects who gave informed consent were assessed for eligibility during this period which lasted for up to 4 weeks.
Treatment period (52 weeks): Subjects had site visits every 4 weeks during this period to receive study drug and complete on-site assessments.
Post-treatment follow-up period (12 weeks): Subject had site visits every 4 weeks with the final visit occurring 16 weeks after the last treatment dose. No study treatment was given during the period.
This study was designed to obtain safety data of QGE031 in 66 Japanese CSU patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent must be obtained prior to participation in the study
- •Male and female subjects ≥ 18 years of age at the time of screening
- •CSU diagnosis for ≥ 6 months
- •Diagnosis of CSU refractory to H1-AH at approved doses at the time of Baseline (Visit 110, Day 1), as defined by all of the following:
- •The presence of itch and hives for ≥ 6 consecutive weeks at any time prior to Visit 1 (Day -28 to Day -14) despite current use of non-sedating H1-AH (at locally approved doses) during this time period
- •UAS7 score (range 0-42) ≥ 16 and HSS7 (range 0-21) ≥ 8 during the 7 days prior to baseline (Visit 110, Day 1)
- •Subjects must be on H1-AH at only approved doses for treatment of CSU for starting at Visit 1 (Day -28 to Day -14)
- •Willing and able to complete a daily symptom electronic Diary (eDiary) for the duration of the study and adhere to the study visit schedules
排除标准
- •History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes (i.e. to murine, chimeric, or human antibodies)
- •Subjects having a clearly defined, predominant trigger of their chronic urticaria (CU) (chronic inducible urticaria (CINDU)) including
- •urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
- •Diseases, other than chronic urticaria, with urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency)
- •Subjects with evidence of helminthic parasitic infection as evidenced by stools being positive for a pathogenic organism according to local guidelines. All subjects will be screened at Visit
- •If stool testing is positive for pathogenic organism, the subject will not enter treatment period and will not be allowed to rescreen
- •Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results (e.g. atopic dermatitis, bullous pemphigoid (BP), dermatitis herpetiformis, senile pruritus, etc)
- •Prior exposure to ligelizumab
- •Any H2 antihistamine, Leukotriene Receptor Antagonist (LTRA) (montelukast or zafirlukast) or H1 antihistamines use at greater than approved dose after Visit 1
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究组 & 干预措施
Ligelizumab 120 mg per 1 mL qw4
Subjects received one subcutaneous injection every 4 weeks at 13 visits during the treatment period
干预措施: Ligelizumab (Biological)
结局指标
主要结局
Safety and Tolerability of Ligelizumab 120 mg q4w Treatment for 12 Months
时间窗: 64 weeks
Participants with treatment emergent adverse events (AEs) and serious adverse events (SAEs) summary for entire study (64 weeks) An AE is any untoward medical occurrence, unfavorable, or unintended sign (including an abnormal laboratory finding), symptom, disease, or injury, temporally associated with the use of a marketed or investigational medicinal product, gene therapy, theragnostic product, or medical device, in patients, clinical-trial subjects, device users, or other persons, whether or not it is considered to be related to or due to the product.
次要结局
- UAS7 Change From Baseline Over Time(Baseline, Weeks 12, 24, 52, and 64)
- Percentage of Participants Who Achieved the Complete UAS7 = 0 Response Over Time(Weeks 12, 24, 52, and 64)
- Percentage of Participants Who Achieved the Complete ISS7 = 0 Response Over Time(Weeks 12, 24, 52, and 64)
- ISS7 Change From Baseline Over Time(Baseline, Weeks 12, 24, 52, and 64)
- HSS7 Change From Baseline Over Time(Baseline, Weeks 12, 24, 52, and 64)
- Percentage of Participants Who Achieved the Complete HSS7 = 0 Response Over Time(Weeks 12, 24, 52, and 64)
- Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) = 0/1 by Visit up to End of Study(Weeks 12, 24, 52, and 64)
- Change From Baseline in the Dermatology Life Quality Index (DLQI)(Baseline, Weeks 12, 24, 52 and 64)